AFFY SEC-arkiveringar - Affymax, Inc.- Årsredovisning, Fullmaktsutlåtande, prospekt

Grundläggande statistik

CIK

1158223

SEC Filings

All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Affymax, Inc.

SEC Filings (Chronological Order)

Denna sida innehåller en komplett, kronologisk lista över SEC-arkiveringar, exklusive ägande-arkiveringar som vi tillhandahåller på andra ställen.

November 14, 2014	15-15D	AFFY / Affymax, Inc. 15-15D - - 15-15D 15-15D 1 doc111880347v1xaffymax-fo.htm 15-15D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number 001-33213 AFFYMAX, INC. (Exact
November 13, 2014	POS AM	AFFY / Affymax, Inc. POS AM - - POS AM POS AM 1 doc111834261v1xaffymax-sx.htm POS AM As filed with the Securities and Exchange Commission on November 13, 2014 Registration No. 333-158080 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-3 REGISTRATION STATEMENT POST-EFFECTIVE AMENDMENT TO REGISTRATION STATEMENT NO. 333-158080 UNDER THE SECURITIES ACT OF 1933 AFFYMAX, INC. (Exact name of registrant as specif
October 8, 2014	S-8 POS	AFFY / Affymax, Inc. S-8 POS - - S-8 POS As filed with the Securities and Exchange Commission on October 7, 2014 Registration No.
October 8, 2014	S-8 POS	AFFY / Affymax, Inc. S-8 POS - - S-8 POS As filed with the Securities and Exchange Commission on October 7, 2014 Registration No.
October 8, 2014	S-8 POS	AFFY / Affymax, Inc. S-8 POS - - S-8 POS As filed with the Securities and Exchange Commission on October 7, 2014 Registration No.
October 7, 2014	S-8 POS	AFFY / Affymax, Inc. S-8 POS - - S-8 POS As filed with the Securities and Exchange Commission on October 7, 2014 Registration No.
October 7, 2014	S-8 POS	AFFY / Affymax, Inc. S-8 POS - - S-8 POS As filed with the Securities and Exchange Commission on October 7, 2014 Registration No.
October 7, 2014	S-8 POS	AFFY / Affymax, Inc. S-8 POS - - S-8 POS As filed with the Securities and Exchange Commission on October 7, 2014 Registration No.
October 7, 2014	S-8 POS	AFFY / Affymax, Inc. S-8 POS - - S-8 POS As filed with the Securities and Exchange Commission on October 7, 2014 Registration No.
September 24, 2014	8-K	Other Events 8-K 1 doc110550042v1xaffymax-8x.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 19, 2014 AFFYMAX, INC. (Exact name of registrant as specified in its charter) Delaware 001-33213 77-0579396 (State or other jurisdictio
September 19, 2014	EX-99.1	XSTELOS ANNOUNCES INTENTION TO VOTE AGAINST AFFYMAX’S PLAN OF LIQUIDATION AT SEPTEMBER 23, 2014 SPECIAL MEETING OF SHAREHOLDERS Exhibit 99.1 XSTELOS ANNOUNCES INTENTION TO VOTE AGAINST AFFYMAX’S PLAN OF LIQUIDATION AT SEPTEMBER 23, 2014 SPECIAL MEETING OF SHAREHOLDERS New York, NY – September 19, 2014 – Xstelos Holdings, Inc. and the members of its Schedule 13D group (collectively, the “Xstelos Group” or “we”) own approximately 5.0% of the outstanding shares of common stock of Affymax, Inc. (OTC: AFFY) (“Affymax” or the “C
September 19, 2014	SC 13D/A	AFFY / Affymax, Inc. / COUCHMAN JONATHAN - AMENDMENT NO. 2 TO THE SCHEDULE 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. 2)1 Affymax, Inc. (Name of Issuer) Common Stock, par value $0.001 (Title of Class of Securities) 00826A109 (CUSIP Number) Jonathan M. Couchman c/o Xstelos
September 9, 2014	DEFA14A	AFFY / Affymax, Inc. DEFA14A - - DEFA14A PLEASE VOTE YOUR SHARES TODAY! September 9, 2014 Dear Stockholder, We are writing to remind you of the importance of voting your shares at the special meeting of stockholders of Affymax, Inc.
August 25, 2014	SC 13D/A	AFFY / Affymax, Inc. / COUCHMAN JONATHAN - AMENDMENT NO. 1 TO THE SCHEDULE 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. 1)1 Affymax, Inc. (Name of Issuer) Common Stock, par value $0.001 (Title of Class of Securities) 00826A109 (CUSIP Number) Jonathan M. Couchman c/o Xstelos
August 25, 2014	SC 13D/A	AFFY / Affymax, Inc. / COUCHMAN JONATHAN - EX. 99.1 - LETTER TO THE BOARD Activist Investment begin 644 ex991sc13da109073012082514.pdf M)5!$1BTQ+C8-"B7Q^??V#0HE,RXT#0HT(#`@;V)J#0H\/`T+T)A2`-"B]$96-O9&5087)M7!E("]);6%G92`- M"B]4>7!E("]83V)J96-T(`T+U=I9'1H(#(U-3`@#0H^/@TJ,BZYJBM([ M$T0T9HZH\B!(@T0-%41U1#14(^CHC4C-'T:D5"-2.J,T5"/HT1)HS1HCZ-$? M1]&:-$?1]'T9HIT9H^C-'T:(JT9HT1FCZ-:.JE.C4A(FA-$;1$(XB=$-$Z$2 MD1$4(VC4B4HG0E"-H2JHUH\C:)T0M&T)4(3B$)+H2I(20CR$B$=$)&T)%T M?1%4)T1#1&(C$:T2$2:/(D(
August 22, 2014	EX-99.1	JOINT FILING AGREEMENT Exhibit 99.1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a Statement on Schedule 13D (including additional amendments thereto) with respect to the shares of Common Stock, $0.001 par value, of Affymax, Inc. This Joint Filing Agreement shall be fil
August 22, 2014	SC 13D	AFFY / Affymax, Inc. / COUCHMAN JONATHAN - SCHEDULE 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. )1 Affymax, Inc. (Name of Issuer) Common Stock, par value $0.001 (Title of Class of Securities) 00826A109 (CUSIP Number) Jonathan M. Couchman c/o Xstelos H
August 18, 2014	DEF 14A	AFFY / Affymax, Inc. DEF 14A - - DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission only (as permitted by Rule 14a-6(e)(2)) x Definitive Proxy State
August 18, 2014	EX-2	Definitive Proxy Statement Special Meeting of Stockholders TO BE HELD ON September 23, 2014 Definitive Proxy Statement Special Meeting of Stockholders TO BE HELD ON September 23, 2014 IMPORTANT SPECIAL MEETING INFORMATION x Using a black ink pen, mark your votes with an X as shown in this example.
August 18, 2014	EX-1	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2014 or o TRANSITION REPORT PURSUANT TO SEC Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2014 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-33213 AFFYMAX, INC. (Exact name of registrant as
August 11, 2014	EX-2	Preliminary Proxy Statement Subject to Completion Special Meeting of Stockholders TO BE HELD ON September 23, 2014 Preliminary Proxy Statement Subject to Completion Special Meeting of Stockholders TO BE HELD ON September 23, 2014 IMPORTANT SPECIAL MEETING INFORMATION x Using a black ink pen, mark your votes with an X as shown in this example.
August 11, 2014	PRE 14A	AFFY / Affymax, Inc. PRE 14A - - PRE 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: x Preliminary Proxy Statement ¨ Confidential, for Use of the Commission only (as permitted by Rule 14a-6(e)(2)) ¨ Definitive Proxy State
August 11, 2014	EX-1	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2014 or o TRANSITION REPORT PURSUANT TO SEC Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2014 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-33213 AFFYMAX, INC. (Exact name of registrant as
August 6, 2014	EX-1	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2014 or o TRANSITION REPORT PURSUANT TO SEC EX-1 2 ex-ax1xaffy063014.htm EX - 1 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2014 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-33213 AFFYMAX
August 6, 2014	EX-2	Preliminary Proxy Statement Subject to Completion Special Meeting of Stockholders TO BE HELD ON September 23, 2014 Preliminary Proxy Statement Subject to Completion Special Meeting of Stockholders TO BE HELD ON September 23, 2014 IMPORTANT SPECIAL MEETING INFORMATION x Using a black ink pen, mark your votes with an X as shown in this example.
August 6, 2014	DEF 14A	AFFY / Affymax, Inc. DEF 14A - - DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: x Preliminary Proxy Statement ¨ Confidential, for Use of the Commission only (as permitted by Rule 14a-6(e)(2)) ¨ Definitive Proxy State
July 31, 2014	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2014 or o TRANSITION REPORT PURSUANT TO SEC Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2014 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934Commission File Number 001-33213 AFFYMAX, INC. (Exact name of registrant as s
July 18, 2014	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 11, 2014 AFFYMAX, INC.
July 18, 2014	EX-99.1	SUPERIOR COURT OF THE STATE OF CALIFORNIA COUNTY OF SANTA CLARA Exhibit 99.1 SUPERIOR COURT OF THE STATE OF CALIFORNIA COUNTY OF SANTA CLARA IN RE AFFYMAX, INC. SHAREHOLDER DERIVATIVE LITIGATION ) ) ) ) ) ) ) ) ) ) ) ) ) ) Lead Case No. 113CV243259 (Consolidated with Case No. 113CV243962) NOTICE OF PROPOSED SETTLEMENT AND SETTLEMENT HEARING Judge: Hon. Peter H. Kirwan Dept.: 1 Date Action Filed: March 19, 2013 This Document Relates To: ALL ACTIONS. TO: ALL CUR
July 18, 2014	EX-99.2	SUPERIOR COURT OF THE STATE OF CALIFORNIA COUNTY OF SANTA CLARA EX-99.2 3 ex-992.htm EX - 99.2 Exhibit 99.2 SUPERIOR COURT OF THE STATE OF CALIFORNIA COUNTY OF SANTA CLARA IN RE AFFYMAX, INC. SHAREHOLDER DERIVATIVE LITIGATION ) ) ) ) ) ) ) ) ) ) ) ) ) Lead Case No. 113CV243259 (Consolidated with Case No. 113CV243962) STIPULATION OF SETTLEMENT Judge: Hon. Peter H. Kirwan Dept.: 1 Date Action Filed: March 19, 2013 This Document Relates To: ALL ACTIONS. STIPULATI
June 24, 2014	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 24, 2014 AFFYMAX, INC.
June 24, 2014	EX-99.1	AFFYMAX BOARD ANNOUNCES DECISION TO DISSOLVE THE COMPANY Corporate Contact: Mark Thompson Chief Financial Officer Affymax, Inc. 650-812-8700 AFFYMAX BOARD ANNOUNCES DECISION TO DISSOLVE THE COMPANY Cupertino, Calif., June 24, 2014 – Affymax, Inc. (AFFY), a biopharmaceutical company, today announced that its Board of Directors has approved the liquidation and dissolution of the company, subject to stockholder approval, and plans to distribute all availab
June 13, 2014	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June [●], 2014 AFFYMAX, INC.
June 13, 2014	EX-99.1	Affymax and Takeda Announce Termination of Omontys® (peginesatide) Product Collaboration and License Agreement Takeda will withdraw the Omontys U.S. New Drug Application (NDA) EX-99.1 2 affymaxtakedaterminationof.htm EX - 99.1 Affymax and Takeda Announce Termination of Omontys® (peginesatide) Product Collaboration and License Agreement Takeda will withdraw the Omontys U.S. New Drug Application (NDA) Cupertino, CA (June 13, 2014) and Osaka, Japan, (June 16, 2014) – Affymax, Inc. and Takeda Pharmaceutical Company Limited (Takeda) announced today that their Omontys® (pegin
May 14, 2014	8-K	Other Events - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2014 AFFYMAX, INC.
May 6, 2014	10-Q	Quarterly Report - 10-Q AFFY 03.31.14 10Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal quarter ended March 31, 2014 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 or Commission File Number 001-33213 AFFYMAX, INC. (Exa
April 30, 2014	DEF 14A	- DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Defin
March 31, 2014	EX-10.29	AFFYMAX INC. EXECUTIVE EMPLOYMENT AGREEMENT ANNE-MARIE DULIEGE Exhibit 10.29 AFFYMAX INC. EXECUTIVE EMPLOYMENT AGREEMENT for ANNE-MARIE DULIEGE This Employment Agreement (“Agreement”) is entered into by and between Anne-Marie Duliege (“Executive”) and Affymax Inc., (the “Company”), effective as of January 31, 2013 (the “Effective Date”). WHEREAS, the Company retains the services of Executive pursuant to that certain Executive Employment Agreement dated Decemb
March 31, 2014	EX-10.49	Consulting Engagement Agreement Consulting Engagement Agreement This Consulting Engagement Agreement (the "Agreement") is made effective as of April 19, 2013 (the "Commencement Date") between The Brenner Group, Inc.
March 31, 2014	EX-10.48	AFFYMAX INC. EXECUTIVE EMPLOYMENT AGREEMENT JEFFREY H. KNAPP Exhibit 10.48 AFFYMAX INC. EXECUTIVE EMPLOYMENT AGREEMENT for JEFFREY H. KNAPP This Employment Agreement (“Agreement”) is entered into by and between Jeffrey H. Knapp (“Executive”) and Affymax Inc., (the “Company”), effective as of January 31, 2013 (the “Effective Date”). WHEREAS, the Company retains the services of Executive pursuant to that certain Executive Employment Agreement dated December 1
March 31, 2014	EX-10.30	AFFYMAX INC. EXECUTIVE EMPLOYMENT AGREEMENT ROBERT F. VENTEICHER Exhibit 10.30 AFFYMAX INC. EXECUTIVE EMPLOYMENT AGREEMENT for ROBERT F. VENTEICHER This Employment Agreement (“Agreement”) is entered into by and between Robert F. Venteicher (“Executive”) and Affymax Inc., (the “Company”), effective as of January 31, 2013 (the “Effective Date”). WHEREAS, the Company retains the services of Executive pursuant to that certain Executive Employment Agreement dated De
March 31, 2014	10-K	Annual Report - 10-K AFFY 12.31.2013 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2013 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-33213 AFFYMAX, INC. (Exact
February 14, 2014	SC 13G/A	AFFY / Affymax, Inc. / Visium Asset Management, LP - SC 13G/A Passive Investment SC 13G/A 1 d675954dsc13ga.htm SC 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Affymax, Inc. (Name of Issuer) COMMON STOCK, $0.001 PER SHARE (Title of Class of Securities) 00826A109 (CUSIP Number) December 31, 2013 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designat
February 13, 2014	SC 13G/A	AFFY / Affymax, Inc. / ORBIMED ADVISORS LLC - SCHEDULE 13G AMENDMENT FILING Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No.
February 10, 2014	SC 13G/A	AFFY / Affymax, Inc. / VANGUARD GROUP INC Passive Investment affymaxinc.htm - Generated by SEC Publisher for SEC Filing SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 2 )* Name of issuer: Affymax Inc Title of Class of Securities: Common Stock CUSIP Number: 00826A109 Date of Event Which Requires Filing of this Statement: December 31, 2013 Check the appropriate box to designate
February 6, 2014	SC 13G/A	AFFY / Affymax, Inc. / OPPENHEIMER FUNDS INC - SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* AFFYMAX, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 00826A109 (CUSIP Number) 12/31/2013 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is fil
November 12, 2013	10-Q/A	Quarterly Report - 10-Q/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A Amendment No. 1 x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2013 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001‑33213
November 12, 2013	10-Q/A	Quarterly Report - 10-Q/A ll UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A Amendment No. 1 x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2013 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001‑33213 A
November 5, 2013	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30, 2013 or o TRANSITION REPORT PURSUANT T Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30, 2013 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-33213 AFFYMAX, INC. (Exact name of registran
August 20, 2013	EX-10.1	SEVENTH AMENDMENT EX-10.1 2 a13-190071ex10d1.htm EX-10.1 Exhibit 10.1 SEVENTH AMENDMENT THIS SEVENTH AMENDMENT (this “Amendment”) is made and entered into as of August 14, 2013, by and between CA-FOOTHILL RESEARCH CENTER LIMITED PARTNERSHIP, a Delaware limited partnership (“Landlord”), and AFFYMAX, INC., a Delaware corporation (“Tenant”). RECITALS A. Landlord (as successor in interest by conversion to EOP-Foothill
August 20, 2013	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 15, 2013 AFFYMAX, INC.
August 16, 2013	8-K	Other Events - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 15, 2013 AFFYMAX, INC.
August 5, 2013	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2013 or o TRANSITION REPORT PURSUANT TO SEC Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2013 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-33213 AFFYMAX, INC. (Exact name of registrant as
June 7, 2013	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Submission of Matters to a Vote of Security Holders - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 4, 2013 AFFYMAX, INC.
May 31, 2013	8-K	Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 28, 2013 AFFYMAX, INC.
May 31, 2013	8-K	Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 28, 2013 AFFYMAX, INC.
May 15, 2013	8-K/A	Current Report 8-K/A 1 a13-1244618ka.htm 8-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment no. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 14, 2013 AFFYMAX, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporatio
May 14, 2013	8-K	- 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 14, 2013 AFFYMAX, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-33213 77-0579396 (Commission File Number) (IR
May 9, 2013	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2013 or o TRANSITION REPORT PURSUANT TO SE Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2013 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-33213 AFFYMAX, INC. (Exact name of registrant as
April 29, 2013	DEF 14A	- DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Defin
April 23, 2013	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 19, 2013 AFFYMAX, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-33213 77-0579396 (Commission File Number) (
April 10, 2013	8-K	- 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 9, 2013 AFFYMAX, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-33213 77-0579396 (Commission File Number) (I
April 4, 2013	8-K	Termination of a Material Definitive Agreement - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 3, 2013 AFFYMAX, INC.
April 2, 2013	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 2, 2013 AFFYMAX, INC.
April 2, 2013	EX-99.1	AFFYMAX REPORTS FOURTH QUARTER AND YEAR-END 2012 FINANCIAL RESULTS Exhibit 99.1 Corporate Contact: Herb Cross Chief Financial Officer Affymax, Inc. 650-812-8847 AFFYMAX REPORTS FOURTH QUARTER AND YEAR-END 2012 FINANCIAL RESULTS PALO ALTO, Calif., April 2, 2013 — Affymax, Inc. (Nasdaq: AFFY) today reported financial results for the fourth quarter and year ended December 31, 2012. The net loss for the fourth quarter of 2012 was $68.3 million (or ($1.85) per share)
April 2, 2013	EX-10.30	AFFYMAX INC. EXECUTIVE EMPLOYMENT AGREEMENT ROBERT F. VENTEICHER Exhibit 10.30 AFFYMAX INC. EXECUTIVE EMPLOYMENT AGREEMENT for ROBERT F. VENTEICHER This Employment Agreement (?Agreement?) is entered into by and between Robert F. Venteicher (?Executive?) and Affymax Inc., (the ?Company?), effective as of January 31, 2013 (the ?Effective Date?). WHEREAS, the Company retains the services of Executive pursuant to that certain Executive Employment Agreement dated De
April 2, 2013	EX-10.48	AFFYMAX INC. EXECUTIVE EMPLOYMENT AGREEMENT JEFFREY H. KNAPP Exhibit 10.48 AFFYMAX INC. EXECUTIVE EMPLOYMENT AGREEMENT for JEFFREY H. KNAPP This Employment Agreement (?Agreement?) is entered into by and between Jeffrey H. Knapp (?Executive?) and Affymax Inc., (the ?Company?), effective as of January 31, 2013 (the ?Effective Date?). WHEREAS, the Company retains the services of Executive pursuant to that certain Executive Employment Agreement dated December 1
April 2, 2013	EX-10.29	AFFYMAX INC. EXECUTIVE EMPLOYMENT AGREEMENT ANNE-MARIE DULIEGE EX-10.29 2 affy12312012ex1029.htm EX-10.29 Exhibit 10.29 AFFYMAX INC. EXECUTIVE EMPLOYMENT AGREEMENT for ANNE-MARIE DULIEGE This Employment Agreement (“Agreement”) is entered into by and between Anne-Marie Duliege (“Executive”) and Affymax Inc., (the “Company”), effective as of January 31, 2013 (the “Effective Date”). WHEREAS, the Company retains the services of Executive pursuant to that certain
April 2, 2013	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2012 or o TRANSITION REPORT PURSUANT TO SE Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2012 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-33213 AFFYMAX, INC. (Exact name of registrant as
March 19, 2013	NT 10-K	- NT 10-K NT 10-K 1 a13-77743nt10k.htm NT 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): x Form 10-K o Form 20-F o Form 11-K o Form 10-Q o Form 10-D o Form N-SAR o Form N-CSR For Period Ended: December 31, 2012 o Transition Report on Form 10-K o Transition Report on Form 20-F o Transition Report on Form 11-K o Transition Repo
March 18, 2013	EX-99.1	AFFYMAX ANNOUNCES REDUCTION IN FORCE TO ALIGN RESOURCES AROUND ONGOING PRODUCT INVESTIGATION Exhibit 99.1 Corporate Contact: Sylvia Wheeler Vice President, Corporate Communications Affymax, Inc. 650-812-8861 AFFYMAX ANNOUNCES REDUCTION IN FORCE TO ALIGN RESOURCES AROUND ONGOING PRODUCT INVESTIGATION Palo Alto, Calif., March 18, 2013 — Affymax, Inc. (Nasdaq: AFFY) today announced that it will reduce its workforce as part of a plan to focus the company’s resources on the ongoing investigati
March 18, 2013	8-K	- 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 18, 2013 AFFYMAX, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-33213 77-0579396 (Commission File Number) (
March 1, 2013	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 27, 2013 AFFYMAX, INC.
February 25, 2013	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 23, 2013 AFFYMAX, INC.
February 25, 2013	EX-99.1	Affymax and Takeda Announce a Nationwide Voluntary Recall of All Lots of OMONTYS® (peginesatide) Injection EX-99.1 2 a13-59591ex99d1.htm EX-99.1 Exhibit 99.1 Affymax, Inc. Takeda Pharmaceuticals U.S.A., Inc Sylvia Wheeler, 650-812-8861 Jocelyn M. Gerst, 224-554-5542 [email protected] [email protected] Takeda Pharmaceutical Company Limited Corporate Communications Dept. (PR/IR) +81-3-3278-2037 Affymax and Takeda Announce a Nationwide Voluntary Recall of All Lots of OMONTYS® (peginesatide)
February 22, 2013	SC 13G/A	AFFY / Affymax, Inc. / VANGUARD GROUP INC Passive Investment affymaxinc.htm - Generated by SEC Publisher for SEC Filing SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 1 )* Name of issuer: Affymax Inc Title of Class of Securities: Common Stock CUSIP Number: 00826A109 Date of Event Which Requires Filing of this Statement: December 31, 2012 Check the appropriate box to designate
February 14, 2013	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 13, 2013 AFFYMAX, INC.
February 14, 2013	EX-99.1	February 13, 2013 Exhibit 99.1 February 13, 2013 Dear Colleagues: We are writing to provide an interim update on the status of our pilot to assess the use of OMONTYS® in the FMCNA dialysis facilities. The purpose of the commercial pilot is to determine the role of OMONTYS® as an alternative Erythropoiesis Stimulating Agent (ESA) on the FMCNA Formulary. The assessment includes efficacy, safety and logistics related
February 14, 2013	SC 13G/A	AFFY / Affymax, Inc. / Visium Asset Management, LP - SCHEDULE 13G (AMENDMENT NO.1) Passive Investment SC 13G/A 1 d487312dsc13ga.htm SCHEDULE 13G (AMENDMENT NO.1) SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Affymax, Inc. (Name of Issuer) COMMON STOCK, $0.001 PER SHARE (Title of Class of Securities) 00826A109 (CUSIP Number) December 31, 2012 (Date of Event Which Requires Filing of this Statement) Check the approp
February 13, 2013	SC 13G	AFFY / Affymax, Inc. / VANGUARD GROUP INC Passive Investment SC 13G 1 affymaxinc.htm SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 0 )* Name of issuer: Affymax Inc Title of Class of Securities: Common Stock CUSIP Number: 00826A109 Date of Event Which Requires Filing of this Statement: December 31, 2012 Check the appropriate box to designate the rule pursuant to which this Sch
February 11, 2013	SC 13G	AFFY / Affymax, Inc. / OPPENHEIMER FUNDS INC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* AFFYMAX, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 00826A109 (CUSIP Number) 12/31/2012 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed
February 5, 2013	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 4, 2013 AFFYMAX, INC.
February 1, 2013	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 30, 2013 AFFYMAX, INC.
January 24, 2013	S-8	- S-8 As filed with the Securities and Exchange Commission on January 24, 2013 Registration No.
January 23, 2013	CORRESP	- Glen Y. Sato T: +1 650 843 5502 [email protected] January 23, 2013 VIA EDGAR SUBMISSION U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549-3628 Mail Stop 3628 Attention: Jim B. Rosenberg Re: Affymax, Inc. Form 10-K for the Fiscal Year Ended December 31, 2011 Filed March 14, 2012 Form 10-Q for the Quarterly Period Ended September 30, 2012 Filed November 9, 2012 Definit
December 21, 2012	CORRESP	- Glen Sato (650) 843-5502 gsato@cooley Via FedEx December 21, 2012 VIA FACSIMILE, FEDERAL EXPRESS AND EDGAR SUBMISSION U.
November 9, 2012	10-Q/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A (Amendment No. 1) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2012 o TRANSI UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A (Amendment No. 1) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2012 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-332
November 9, 2012	EX-10.51	AFFYMAX INC. EXECUTIVE EMPLOYMENT AGREEMENT Karin L. Walker Exhibit 10.51 AFFYMAX INC. EXECUTIVE EMPLOYMENT AGREEMENT for Karin L. Walker This Employment Agreement (“Agreement”) is entered into by and between Karin L. Walker (“Executive”) and Affymax Inc., (the “Company”), effective as of October 1, 2012 (the “Effective Date”). WHEREAS, the Company desires to employ Executive to provide personal services to the Company, and wishes to provide Executive with
November 9, 2012	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2012 o TRANSITION REPORT PURSUANT Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2012 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-33213
November 8, 2012	EX-99.1	AFFYMAX REPORTS THIRD QUARTER 2012 FINANCIAL RESULTS Exhibit 99.1 Corporate Contact: Sylvia Wheeler Vice President, Corporate Communications Affymax, Inc. 650-812-8861 AFFYMAX REPORTS THIRD QUARTER 2012 FINANCIAL RESULTS PALO ALTO, Calif., November 8, 2012 — Affymax, Inc. (Nasdaq: AFFY) today reported financial results for the third quarter ended September 30, 2012. The net loss for the third quarter of 2012 was $24.6 million (or ($0.68) per share)
November 8, 2012	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 a12-2654118k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 8, 2012 AFFYMAX, INC. (Exact name of registrant as specified in its charter) Delaware 001-33213 77-0579396 (State or other jurisdiction of (Commissio
October 3, 2012	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 1, 2012 AFFYMAX, INC.
October 3, 2012	EX-99.1	AFFYMAX APPOINTS KARIN L. WALKER AS VICE PRESIDENT OF FINANCE AND CHIEF ACCOUNTING OFFICER Exhibit 99.1 AFFYMAX APPOINTS KARIN L. WALKER AS VICE PRESIDENT OF FINANCE AND CHIEF ACCOUNTING OFFICER Palo Alto, Calif., October 2, 2012 — Affymax, Inc. (Nasdaq: AFFY) today announced that it has appointed Karin L. Walker, CPA, as vice president of finance and chief accounting officer. Ms. Walker has over two decades of financial management experience, including in the biotechnology and pharmace
August 8, 2012	EX-10.5	AFFYMAX, INC. AMENDED AND RESTATED 2006 EQUITY INCENTIVE PLAN APPROVED BY THE BOARD: JULY 7, 2006 APPROVED BY THE STOCKHOLDERS: NOVEMBER 22, 2006 AS AMENDED BY THE BOARD ON OCTOBER 29, 2009 AS AMENDED BY THE BOARD ON MARCH 2, 2011 AS AMENDED BY THE B Exhibit 10.5 AFFYMAX, INC. AMENDED AND RESTATED 2006 EQUITY INCENTIVE PLAN APPROVED BY THE BOARD: JULY 7, 2006 APPROVED BY THE STOCKHOLDERS: NOVEMBER 22, 2006 AS AMENDED BY THE BOARD ON OCTOBER 29, 2009 AS AMENDED BY THE BOARD ON MARCH 2, 2011 AS AMENDED BY THE BOARD ON JUNE 13, 2012 TERMINATION DATE: JULY 6, 2016 1. GENERAL. (a) Successor and Continuation of Prior Plan. The Plan is intended as th
August 8, 2012	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2012 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-33213 AFFY
August 8, 2012	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2012 AFFYMAX, INC.
August 8, 2012	EX-99.1	AFFYMAX REPORTS SECOND QUARTER 2012 FINANCIAL RESULTS Exhibit 99.1 Corporate Contact: Sylvia Wheeler Vice President, Corporate Communications Affymax, Inc. 650-812-8861 AFFYMAX REPORTS SECOND QUARTER 2012 FINANCIAL RESULTS PALO ALTO, Calif., August 8, 2012 — Affymax, Inc. (Nasdaq: AFFY) today reported financial results for the second quarter ended June 30, 2012. The net loss for the second quarter of 2012 was $32.0 million (or ($0.89) per share) comp
July 12, 2012	EX-99.1	TAKEDA AND AFFYMAX ANNOUNCE SUPPLY AGREEMENT FOR OMONTYS® (PEGINESATIDE) INJECTION WITH FRESENIUS MEDICAL CARE NORTH AMERICA Exhibit 99.1 Sylvia Wheeler Jocelyn M. Gerst Vice President, Corporate Communications Corporate Communications Affymax, Inc. Takeda Pharmaceuticals U.S.A., Inc. 650-812-8861 224-554-5542 TAKEDA AND AFFYMAX ANNOUNCE SUPPLY AGREEMENT FOR OMONTYS® (PEGINESATIDE) INJECTION WITH FRESENIUS MEDICAL CARE NORTH AMERICA Deerfield, Ill. and Palo Alto, Calif.— July 12, 2012 — Takeda Pharmaceuticals U.S.A. (TP
July 12, 2012	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 12, 2012 AFFYMAX, INC.
July 2, 2012	10-Q/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A Amendment No. 1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A Amendment No. 1 x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2012 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-33213 AFF
July 2, 2012	EX-10.49	U.S. CO-PROMOTION AGREEMENT AFFYMAX, INC. TAKEDA PHARMACEUTICALS U.S.A., INC. February 24, 2012 Exhibit 10.49 [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. U.S. CO-PROMOTION AGREEMENT AFFYMAX, INC. and TAKEDA PHARMACEUTICALS U.S.A., INC. February 24, 2012 TABLE OF CONTENTS PAGE 1. Definitions 1
June 19, 2012	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Entry into a Material Definitive Agreement, Submission of Matters to a Vote of Security Holders - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 13, 2012 AFFYMAX, INC.
May 9, 2012	EX-4.5	WARRANT TO PURCHASE STOCK Exhibit 4.5 THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR THE SECURITIES LAWS OF ANY STATE AND, EXCEPT AS SET FORTH IN SECTIONS 5.3 AND 5.4 BELOW, MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED UNLESS AND UNTIL REGISTERED UNDER SAID ACT AND LAWS OR, IN THE OPINION OF LEGAL COUNSEL IN FORM AND SUBSTAN
May 9, 2012	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2012 o TRANSITION REPORT PURSUANT TO Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2012 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-33213 AFF
May 9, 2012	EX-10.50	LOAN AND SECURITY AGREEMENT Exhibit 10.50 LOAN AND SECURITY AGREEMENT THIS LOAN AND SECURITY AGREEMENT (this “Agreement”) dated as of March 26, 2012 (the “Effective Date”) among OXFORD FINANCE LLC, a Delaware limited liability company with an office located at 133 North Fairfax Street, Alexandria, Virginia 22314 (“Oxford”), as collateral agent (in such capacity, “Collateral Agent”), the Lenders listed on Schedule 1.1 hereof
May 9, 2012	EX-10.49	U.S. CO-PROMOTION AGREEMENT AFFYMAX, INC. TAKEDA PHARMACEUTICALS U.S.A., INC. February 24, 2012 Exhibit 10.49 [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. U.S. CO-PROMOTION AGREEMENT AFFYMAX, INC. and TAKEDA PHARMACEUTICALS U.S.A., INC. February 24, 2012 TABLE OF CONTENTS PAGE 1. Definitions 1
May 9, 2012	EX-4.6	WARRANT TO PURCHASE STOCK Exhibit 4.6 THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?ACT?), OR THE SECURITIES LAWS OF ANY STATE AND, EXCEPT AS SET FORTH IN SECTIONS 5.3 AND 5.4 BELOW, MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED UNLESS AND UNTIL REGISTERED UNDER SAID ACT AND LAWS OR, IN THE OPINION OF LEGAL COUNSEL IN FORM AND SUBSTAN
May 7, 2012	EX-99.1	AFFYMAX REPORTS FIRST QUARTER 2012 FINANCIAL RESULTS — $58 million in milestones earned — Exhibit 99.1 Corporate Contact: Sylvia Wheeler Vice President, Corporate Communications Affymax, Inc. 650-812-8861 AFFYMAX REPORTS FIRST QUARTER 2012 FINANCIAL RESULTS — $58 million in milestones earned — PALO ALTO, Calif., May 7, 2012 — Affymax, Inc. (Nasdaq: AFFY) today reported financial results for the first quarter ended March 31, 2012. The net income for the first quarter of 2012 was $31.5 m
May 7, 2012	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 a12-1115818k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 7, 2012 AFFYMAX, INC. (Exact name of registrant as specified in its charter) Delaware 001-33213 77-0579396 (State or other jurisdiction of (Commission Fil
April 27, 2012	EX-99.1	OMONTYS® (PEGINESATIDE) INJECTION NOW AVAILABLE FOR ADULT CHRONIC KIDNEY DISEASE (CKD) PATIENTS ON DIALYSIS IN THE UNITED STATES — Only Once-Monthly Erythropoiesis-Stimulating Agent Launched In The United States — Exhibit 99.1 Sylvia Wheeler Takeda Pharmaceutical Company Limited Vice President, Corporate Communications Corporate Communications Dept. (PR/IR) Affymax, Inc. +81-3-3278-2037 650-812-8861 Jocelyn Gerst Corporate Communications Takeda Pharmaceuticals U.S.A. 224-554-5542 OMONTYS® (PEGINESATIDE) INJECTION NOW AVAILABLE FOR ADULT CHRONIC KIDNEY DISEASE (CKD) PATIENTS ON DIALYSIS IN THE UNITED STATES
April 27, 2012	8-K	Financial Statements and Exhibits, Other Events - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 24, 2012 AFFYMAX, INC.
April 24, 2012	DEF 14A	- DEF 14A QuickLinks - Click here to rapidly navigate through this document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
April 5, 2012	SC 13G	AFFY / Affymax, Inc. / Visium Asset Management, LP - SCHEDULE 13G Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* AFFYMAX INC. (Name of Issuer) COMMON STOCK, $.001 PER SHARE (Title of Class of Securities) 00826A109 (CUSIP Number) March 27, 2012 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is
March 28, 2012	8-K	Financial Statements and Exhibits, Other Events - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 27, 2012 AFFYMAX, INC.
March 28, 2012	EX-99.1	AFFYMAX AND TAKEDA ANNOUNCE FDA APPROVAL OF OMONTYS® (PEGINESATIDE) INJECTION FOR THE TREATMENT OF ANEMIA DUE TO CHRONIC KIDNEY DISEASE (CKD) IN ADULT PATIENTS ON DIALYSIS — Only Once-Monthly ESA Treatment For Dialysis Patients To Be Made Available I Exhibit 99.1 Sylvia Wheeler Vice President, Corporate Communications Affymax, Inc. 650-812-8861 Takeda Pharmaceutical Company Limited Corporate Communications Dept. (PR/IR) +81-3-3278-2037 Josephine Zammuto Corporate Communications Takeda Global Research & Development Center, Inc. 224-554-2795 AFFYMAX AND TAKEDA ANNOUNCE FDA APPROVAL OF OMONTYS® (PEGINESATIDE) INJECTION FOR THE TREATMENT OF ANEMIA
March 27, 2012	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 26, 2012 AFFYMAX, INC.
March 14, 2012	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Use these links to rapidly review the document AFFYMAX, INC. TABLE OF CONTENTS Item 8. Financial Statements and Supplementary Data. Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ý ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2011 or o TRANSITION REPORT PURSUANT TO SE
March 14, 2012	EX-10.47	SETTLEMENT AND LICENSE AGREEMENT Exhibit 10.47 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. SETTLEMENT AND LICENSE AGREEMENT This SETTLEMENT AND LICENSE AGREEMENT (this “Agreement”) is entered into effective as of the November 7, 2011 (the “Effective Date”) by
March 14, 2012	EX-10.48	THIRD AMENDMENT TO COLLABORATION AND LICENSE AGREEMENTS Exhibit 10.48 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. THIRD AMENDMENT TO COLLABORATION AND LICENSE AGREEMENTS This Amendment to Collaboration and License Agreements (the “Amendment”) is entered into on November 7, 2011 (the
March 14, 2012	EX-99.1	AFFYMAX® REPORTS YEAR END 2011 FINANCIAL RESULTS - Provides Financial Guidance for 2012 - Exhibit 99.1 Corporate Contact: Sylvia Wheeler Vice President, Corporate Communications Affymax, Inc. 650-812-8861 AFFYMAX® REPORTS YEAR END 2011 FINANCIAL RESULTS - Provides Financial Guidance for 2012 - PALO ALTO, Calif., March 14, 2012 — Affymax, Inc. (Nasdaq: AFFY) today reported financial results for the year ended December 31, 2011. The net loss for the year ended December 31, 2011 was $61.4
March 14, 2012	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 14, 2012 AFFYMAX, INC.
February 27, 2012	EX-99.1	AFFYMAX TO RECEIVE $5 MILLION MILESTONE PAYMENT FOR ACCEPTANCE OF EUROPEAN MARKETING AUTHORIZATION APPLICATION FOR PEGINESATIDE Exhibit 99.1 Corporate Contact: Sylvia Wheeler Vice President, Corporate Communications Affymax, Inc. 650-812-8861 AFFYMAX TO RECEIVE $5 MILLION MILESTONE PAYMENT FOR ACCEPTANCE OF EUROPEAN MARKETING AUTHORIZATION APPLICATION FOR PEGINESATIDE Palo Alto, Calif., February 27, 2012 — Affymax, Inc. (Nasdaq: AFFY) today announced that it will receive a $5 million development milestone payment from Take
February 27, 2012	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 24, 2012 AFFYMAX, INC.
February 14, 2012	SC 13G/A	AFFY / Affymax, Inc. / WELLINGTON MANAGEMENT GROUP LLP - DISCLOSURE DOCUMENT Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Affymax, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 00826A109 (CUSIP Number) December 31, 2011 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule
February 13, 2012	SC 13G/A	AFFY / Affymax, Inc. / ProQuest Investments IV, L.P. - SCHEDULE 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G (Amendment No.
February 9, 2012	SC 13D/A	AFFY / Affymax, Inc. / CREDIT SUISSE AG/ Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 3)* Affymax, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 00826A109 (CUSIP Number) Ivy Dodes Credit Suisse AG Eleven Madison Avenue, New York, NY 10010 (212) 325-2000 (Name, Address and Telephone Number of P
February 3, 2012	S-8	- S-8 As filed with the Securities and Exchange Commission on February 3, 2012 Registration No.
February 2, 2012	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 31, 2012 AFFYMAX, INC.
December 15, 2011	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 15, 2011 AFFYMAX, INC. (Ex UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 15, 2011 AFFYMAX, INC.
December 15, 2011	EX-99.1	TAKEDA AND AFFYMAX PROVIDE UPDATE ON PEGINESATIDE COMMERCIALIZATION RIGHTS IN JAPAN Exhibit 99.1 Corporate Contacts: Seizo Masuda Takeda Pharmaceutical Company Limited Corporate Communications Dept. (PR/IR) +81-3-3278-2037 Sylvia Wheeler Vice President, Corporate Communications Affymax, Inc. +1-650-812-8861 TAKEDA AND AFFYMAX PROVIDE UPDATE ON PEGINESATIDE COMMERCIALIZATION RIGHTS IN JAPAN Osaka, Japan, December 16, 2011 and Palo Alto, Ca., December 15, 2011, ? Takeda Pharmaceuti
December 8, 2011	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 7, 2011 AFFYMAX, INC.
December 8, 2011	EX-99.1	FDA ADVISORY COMMITTEE VOTED IN FAVOR OF BENEFIT/RISK PROFILE FOR PEGINESATIDE FOR TREATMENT OF ANEMIA IN CHRONIC KIDNEY DISEASE PATIENTS ON DIALYSIS EXHIBIT 99.1 Corporate Contacts: Sylvia Wheeler Vice President, Corporate Communications Affymax, Inc. 650-812-8861 Josephine Zammuto Corporate Communications Takeda Global Research & Development Center, Inc. 224-554-2795 Takeda Pharmaceutical Company Limited Corporate Communications Dept. (PR/IR) +81-3-3278-2037 FDA ADVISORY COMMITTEE VOTED IN FAVOR OF BENEFIT/RISK PROFILE FOR PEGINESATIDE FOR TR
November 9, 2011	EX-99.1	AFFYMAX? REPORTS THIRD QUARTER 2011 FINANCIAL RESULTS Exhibit 99.1 Corporate Contact: Sylvia Wheeler Vice President, Corporate Communications Affymax, Inc. 650-812-8861 AFFYMAX? REPORTS THIRD QUARTER 2011 FINANCIAL RESULTS PALO ALTO, Calif., November 9, 2011 ? Affymax, Inc. (Nasdaq: AFFY) today reported financial results for the third quarter ended September 30, 2011. The net loss for the third quarter of 2011 was $9.8 million compared to a net loss
November 9, 2011	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2011 AFFYMAX, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-33213 77-0579396 (Commission File Number)
November 9, 2011	EX-99.1	AFFYMAX AND JANSSEN BIOTECH SETTLE PATENT DISPUTE Ends Ongoing Litigation and Legal Expenses Exhibit 99.1 Corporate Contact: Sylvia Wheeler Vice President, Corporate Communications Affymax, Inc. 650-812-8861 AFFYMAX AND JANSSEN BIOTECH SETTLE PATENT DISPUTE Ends Ongoing Litigation and Legal Expenses Palo Alto, Calif., November 9, 2011 ? Affymax, Inc. (Nasdaq: AFFY) today announced that it has reached a global settlement agreement with Janssen Biotech, Inc. (a subsidiary of Johnson & Johns
November 9, 2011	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2011 AFFYMAX, INC. (Exa UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2011 AFFYMAX, INC.
November 9, 2011	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2011 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-33213
October 21, 2011	EX-99.1	Joint Filing Agreement Exhibit 99.1 Joint Filing Agreement The undersigned hereby agree that the Statement on Schedule 13G dated October 21, 2011 with respect to the shares of Common Stock of Affymax, Inc., and any amendments thereto executed by each and any of the undersigned shall be filed on behalf of each of the undersigned pursuant to and in accordance with the provisions of Rule 13d-1(k)(1) under the Securities Ex
October 21, 2011	SC 13G	UNITED STATES UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. )1 Affymax, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 00826A 10 9 (CUSIP Number) October 14, 2011 (D
September 30, 2011	8-K/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 25, 2011 AF UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K/A (Amendment No.
September 7, 2011	CORRESP	September 7, 2011 September 7, 2011 U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Attn: Jeffrey Riedler Karen Ubell Re: Affymax, Inc. Registration Statement on Form S-3 Filed August 8, 2011 Registration File No. 333-176137 Ladies and Gentlemen: The undersigned registrant hereby requests that the U.S. Securities and Exchange Commission (the ?Commissio
August 11, 2011	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 10, 2011 AFFYMAX, INC.
August 11, 2011	EX-99.1	AFFYMAX® RECEIVES $10 MILLION MILESTONE PAYMENT FOR FDA FILING OF NEW DRUG APPLICATION FOR HEMATIDE™/PEGINESATIDE Exhibit 99.1 Corporate Contact: Sylvia Wheeler Vice President, Corporate Communications Affymax, Inc. 650-812-8861 AFFYMAX? RECEIVES $10 MILLION MILESTONE PAYMENT FOR FDA FILING OF NEW DRUG APPLICATION FOR HEMATIDE?/PEGINESATIDE PALO ALTO, Calif., August 10, 2011 ? Affymax, Inc. (Nasdaq: AFFY) today announced that it has received a $10 million development milestone payment from Takeda Pharmaceutic
August 11, 2011	EX-99.2	AFFYMAX ANNOUNCES ASSIGNMENT OF MARCH 27, 2012 PDUFA DATE FOR PEGINESATIDE NEW DRUG APPLICATION Exhibit 99.2 Corporate Contact: Sylvia Wheeler Vice President, Corporate Communications Affymax, Inc. 650-812-8861 AFFYMAX ANNOUNCES ASSIGNMENT OF MARCH 27, 2012 PDUFA DATE FOR PEGINESATIDE NEW DRUG APPLICATION Palo Alto, Calif., August 11, 2011 — Affymax, Inc. (Nasdaq: AFFY) today announced that the U.S. Food and Drug Administration has assigned a Prescription Drug User Fee Act (PDUFA) action dat
August 8, 2011	EX-4.12	AFFYMAX, INC. , AS WARRANT AGENT FORM OF PREFERRED STOCK WARRANT AGREEMENT DATED AS OF EXHIBIT 4.12 AFFYMAX, INC. and , AS WARRANT AGENT FORM OF PREFERRED STOCK WARRANT AGREEMENT DATED AS OF AFFYMAX, INC. FORM OF PREFERRED STOCK WARRANT AGREEMENT PREFERRED STOCK WARRANT AGREEMENT (this “Agreement”), dated as of between Affymax, Inc., a Delaware corporation (the “Company”) and , a [corporation] [national banking association] organized and existing under the laws of and having a corpo
August 8, 2011	EX-99.1	AFFYMAX® REPORTS SECOND QUARTER 2011 FINANCIAL RESULTS - Reaffirms Guidance for 2011 - Exhibit 99.1 Corporate Contact: Sylvia Wheeler Vice President, Corporate Communications Affymax, Inc. 650-812-8861 AFFYMAX? REPORTS SECOND QUARTER 2011 FINANCIAL RESULTS - Reaffirms Guidance for 2011 - PALO ALTO, Calif., August 8, 2011 ? Affymax, Inc. (Nasdaq: AFFY) today reported financial results for the second quarter ended June 30, 2011. The net loss for the second quarter of 2011 was $12.5 mi
August 8, 2011	EX-4.8	AFFYMAX, INC., Dated as of [·], 20[·] Subordinated Debt Securities EXHIBIT 4.8 AFFYMAX, INC., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [?], 20[?] Subordinated Debt Securities ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 3 Section 2.01 Designation and Terms of Securities 3 Section 2.02 Form of Securities and Trustee?s Certificate 5 Section 2.03 Denomin
August 8, 2011	S-3	As filed with the Securities and Exchange Commission on August 8, 2011 Use these links to rapidly review the document TABLE OF CONTENTS Table of Contents As filed with the Securities and Exchange Commission on August 8, 2011 Registration No.
August 8, 2011	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2011 AFFYMAX, INC. (Exa UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2011 AFFYMAX, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-33213 77-0579396 (Commission File Number) (
August 8, 2011	EX-12.1	Statement of Computation of Ratio of Earnings to Fixed Charges and Ratio of Combined Fixed Charges and Preferred Stock Dividends to Earnings Exhibit 12.1 Statement of Computation of Ratio of Earnings to Fixed Charges and Ratio of Combined Fixed Charges and Preferred Stock Dividends to Earnings Six months ended June 30, Year Ended December 31, 2011 2010 2009 2008 2007 2006 Earnings: Net loss $ (22,110 ) $ (14,075 ) $ (77,942 ) $ (86,228 ) $ (37,712 ) $ (48,288 ) Plus: Fixed charges $ 547 $ 969 $ 715 $ 879 $ 812 $ 1,051 Earnings, as defi
August 8, 2011	EX-4.13	AFFYMAX, INC. , AS WARRANT AGENT FORM OF DEBT SECURITIES WARRANT AGREEMENT DATED AS OF EXHIBIT 4.13 AFFYMAX, INC. and , AS WARRANT AGENT FORM OF DEBT SECURITIES WARRANT AGREEMENT DATED AS OF AFFYMAX, INC. FORM OF DEBT SECURITIES WARRANT AGREEMENT DEBT SECURITIES WARRANT AGREEMENT (this ?Agreement?), dated as of between AFFYMAX, INC., a Delaware corporation (the ?Company?) and , a [corporation] [national banking association] organized and existing under the laws of and having a corpo
August 8, 2011	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2011 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-33213 AFFY
August 8, 2011	EX-10.45	AMENDMENT NO. 2 TO COMMON STOCK PURCHASE AGREEMENT Exhibit 10.45 AMENDMENT NO. 2 TO COMMON STOCK PURCHASE AGREEMENT This Amendment No. 2 (the ?Amendment?) is entered into this 2nd day of May 2011 (?Amendment Effective Date?) by and between Azimuth Opportunity Ltd., an international business company incorporated under the laws of the British Virgin Islands (the ?Investor?), and Affymax, Inc., a corporation organized and existing under the laws of t
August 8, 2011	EX-4.7	AFFYMAX, INC., Dated as of [·], 20[·] Senior Debt Securities EXHIBIT 4.7 AFFYMAX, INC., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [?], 20[?] Senior Debt Securities Table of Contents Page ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 3 Section 2.01 Designation and Terms of Securities 3 Section 2.02 Form of Securities and Trustee?s Certificate 5 Sec
August 8, 2011	EX-4.11	AFFYMAX, INC. , AS WARRANT AGENT FORM OF COMMON STOCK WARRANT AGREEMENT DATED AS OF EXHIBIT 4.11 AFFYMAX, INC. and , AS WARRANT AGENT FORM OF COMMON STOCK WARRANT AGREEMENT DATED AS OF AFFYMAX, INC. FORM OF COMMON STOCK WARRANT AGREEMENT COMMON STOCK WARRANT AGREEMENT (this ?Agreement?), dated as of between Affymax, Inc., a Delaware corporation (the ?Company?) and , a [corporation] [national banking association] organized and existing under the laws of and having a corporate trus
July 27, 2011	EX-99.1	AFFYMAX AND TAKEDA ANNOUNCE FDA ACCEPTANCE OF NEW DRUG APPLICATION FOR PEGINESATIDE Exhibit 99.1 Sylvia Wheeler Vice President, Corporate Communications Affymax, Inc. 650-812-8861 Josephine Zammuto Corporate Communications Takeda Global Research & Development Center, Inc. 224-554-2795 AFFYMAX AND TAKEDA ANNOUNCE FDA ACCEPTANCE OF NEW DRUG APPLICATION FOR PEGINESATIDE Palo Alto, Calif., & Deerfield, Ill., July 27, 2011 ? Affymax, Inc. (Nasdaq: AFFY) and Takeda Global Research & De
July 27, 2011	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 27, 2011 AFFYMAX, INC.
July 5, 2011	EX-99	EX-99 Exhibit 99.1 (1) Kathleen D. LaPorte ("LaPorte"), in her capacity as a member of the investment committees of DLJCC (as defined below) and of DLJLBO (as defined below), may be deemed to beneficially own the shares as to which this Form 4 relates. Ms. LaPorte disclaims beneficial ownership of such shares except to the extent of her pecuniary interest therein. Sprout Capital IX, L.P. ("Sprout IX"),
June 30, 2011	EX-99	EX-99 Exhibit 99.1 (1) Kathleen D. LaPorte ("LaPorte"), in her capacity as a member of the investment committees of DLJCC (as defined below) and of DLJLBO (as defined below), may be deemed to beneficially own the shares as to which this Form 4 relates. Ms. LaPorte disclaims beneficial ownership of such shares except to the extent of her pecuniary interest therein. Sprout Capital IX, L.P. ("Sprout IX"),
May 31, 2011	EX-99.1	AFFYMAX AND TAKEDA ANNOUNCE THE SUBMISSION OF A NEW DRUG APPLICATION FOR PEGINESATIDE FOR THE TREATMENT OF ANEMIA ASSOCIATED WITH CHRONIC RENAL FAILURE IN PATIENTS ON DIALYSIS Exhibit 99.1 Sylvia Wheeler Vice President, Corporate Communications Affymax, Inc. 650-812-8861 Mihoko Shinomiya Corporate Communications Department Takeda Pharmaceutical Company Limited +81-3-3278-2292 Josephine Zammuto Corporate Communications Takeda Global Research & Development Center, Inc. 224-554-2795 AFFYMAX AND TAKEDA ANNOUNCE THE SUBMISSION OF A NEW DRUG APPLICATION FOR PEGINESATIDE FOR T
May 31, 2011	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 31, 2011 AFFYMAX, INC. (Exact n UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 31, 2011 AFFYMAX, INC.
May 26, 2011	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 25, 2011 AFFYMAX, INC. (Exact n UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 25, 2011 AFFYMAX, INC.
May 18, 2011	EX-99	EX-99 Exhibit 99.1 (1) Kathleen D. LaPorte ("LaPorte"), in her capacity as a member of the investment committees of DLJCC (as defined below) and of DLJLBO (as defined below), may be deemed to beneficially own the shares as to which this Form 4 relates. Ms. LaPorte disclaims beneficial ownership of such shares except to the extent of her pecuniary interest therein. Sprout Capital IX, L.P. ("Sprout IX"),
May 9, 2011	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2011 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-33213 AFF
May 9, 2011	EX-10.44	AFFYMAX, INC. 4001 Miranda Avenue Palo Alto, CA 94304 Exhibit 10.44 AFFYMAX, INC. 4001 Miranda Avenue Palo Alto, CA 94304 January 5, 2011 Arlene Morris c/o Affymax, Inc. 4001 Miranda Avenue Palo Alto, CA 94304 Dear Arlene: In connection with your termination from employment with the Company, this letter sets forth the terms of the separation and consulting agreement (the “Agreement”) between you and Affymax, Inc. (the “Company”). 1. Resignation. As d
May 9, 2011	EX-10.41	AFFYMAX INC. EXECUTIVE EMPLOYMENT AGREEMENT John A. Orwin Exhibit 10.41 AFFYMAX INC. EXECUTIVE EMPLOYMENT AGREEMENT for John A. Orwin This Employment Agreement (“Agreement”) is entered into by and between John A. Orwin (“Executive”) and Affymax Inc., (the “Company”), effective as of February 1, 2011 (the “Effective Date”). WHEREAS, the Company retains the services of Executive pursuant to that certain Executive Employment Agreement dated February 19, 201
May 9, 2011	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2011 AFFYMAX, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-33213 77-0579396 (Commission File Number) (IRS
May 9, 2011	EX-99.1	AFFYMAX® REPORTS FIRST QUARTER 2011 FINANCIAL RESULTS Exhibit 99.1 Corporate Contact: Sylvia Wheeler Vice President, Corporate Communications Affymax, Inc. 650-812-8861 AFFYMAX? REPORTS FIRST QUARTER 2011 FINANCIAL RESULTS PALO ALTO, Calif., May 9, 2011 ? Affymax, Inc. (Nasdaq: AFFY) today reported financial results for the first quarter ended March 31, 2011. The net loss for the first quarter of 2011 was $9.6 million compared to a net loss of $7.9 m
May 9, 2011	EX-10.5	AFFYMAX, INC. AMENDED AND RESTATED 2006 EQUITY INCENTIVE PLAN APPROVED BY THE BOARD: JULY 7, 2006 APPROVED BY THE STOCKHOLDERS: NOVEMBER 22, 2006 AS AMENDED BY THE BOARD ON OCTOBER 29, 2009 AS AMENDED BY THE BOARD ON MARCH 2, 2011 TERMINATION DATE: J Exhibit 10.5 AFFYMAX, INC. AMENDED AND RESTATED 2006 EQUITY INCENTIVE PLAN APPROVED BY THE BOARD: JULY 7, 2006 APPROVED BY THE STOCKHOLDERS: NOVEMBER 22, 2006 AS AMENDED BY THE BOARD ON OCTOBER 29, 2009 AS AMENDED BY THE BOARD ON MARCH 2, 2011 TERMINATION DATE: JULY 6, 2016 1. GENERAL. (a) Successor and Continuation of Prior Plan. The Plan is intended as the successor to and continuation of the Af
April 7, 2011	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) QuickLinks - Click here to rapidly navigate through this document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
March 30, 2011	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 30, 2011 AFFYMAX, INC.
March 22, 2011	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 21, 2011 AFFYMAX, INC.
March 18, 2011	EX-1.1	Common Stock 8,474,576 Shares AFFYMAX, INC. UNDERWRITING AGREEMENT Exhibit 1.1 Common Stock 8,474,576 Shares AFFYMAX, INC. UNDERWRITING AGREEMENT March 18, 2011 Lazard Capital Markets LLC As Representative of the several Underwriters c/o Lazard Capital Markets LLC 30 Rockefeller Plaza New York, New York 10020 Dear Sirs and Madams: 1. INTRODUCTORY. Affymax, Inc., a Delaware corporation (the ?Company?), proposes to sell, pursuant to the terms of this Agreement, to
March 18, 2011	424B5	8,474,576 Shares Common Stock Use these links to rapidly review the document TABLE OF CONTENTS TABLE OF CONTENTS Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No.
March 18, 2011	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 18, 2011 AFFYMAX, INC. (Exact UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 18, 2011 AFFYMAX, INC.
March 18, 2011	EX-99.1	AFFYMAX ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK Exhibit 99.1 Sylvia Wheeler Vice President, Corporate Communication Affymax, Inc. 650-812-8861 AFFYMAX ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK PALO ALTO, Calif., March 18, 2011, Affymax, Inc. (Nasdaq: AFFY), today announced the pricing of an underwritten public offering of 8,474,576 shares of its common stock at a price to the public of $5.90 per share. The gross proceeds to Affymax f
March 17, 2011	424B5	SUBJECT TO COMPLETION, DATED MARCH 17, 2011 Use these links to rapidly review the document TABLE OF CONTENTS TABLE OF CONTENTS Table of Contents The information in this prospectus supplement, relating to an effective registration statement under the Securities Act of 1933, as amended, is not complete and may be changed.
March 11, 2011	EX-10.42	AFFYMAX INC. EXECUTIVE EMPLOYMENT AGREEMENT Herb C. Cross Exhibit 10.42 AFFYMAX INC. EXECUTIVE EMPLOYMENT AGREEMENT for Herb C. Cross This Employment Agreement (“Agreement”) is entered into by and between Herb C. Cross (“Executive”) and Affymax Inc., (the “Company”), effective as of March 4, 2011 (the “Effective Date”). WHEREAS, the Company retains the services of Executive pursuant to that certain Executive Employment Agreement dated November 5, 2010 (t
March 11, 2011	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Use these links to rapidly review the document AFFYMAX, INC. TABLE OF CONTENTS Item 8. Financial Statements and Supplementary Data. Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2010 or o TRANSITION REPORT PURSUANT TO SE
March 11, 2011	EX-10.43	SIXTH AMENDMENT Exhibit 10.43 SIXTH AMENDMENT THIS SIXTH AMENDMENT (this “Amendment”) is made and entered into as of December 21, 2010, by and between CA-FOOTHILL RESEARCH CENTER LIMITED PARTNERSHIP, a Delaware limited partnership (“Landlord”), and AFFYMAX, INC., a Delaware corporation (“Tenant”). RECITALS A. Landlord (as successor in interest by conversion to EOP-Foothill Research Center, L.L.C., a Delaware limi
March 10, 2011	EX-99.1	AFFYMAX® REPORTS YEAR END 2010 FINANCIAL RESULTS Exhibit 99.1 Corporate Contact: Sylvia Wheeler Vice President, Corporate Communications Affymax, Inc. 650-812-8861 AFFYMAX? REPORTS YEAR END 2010 FINANCIAL RESULTS PALO ALTO, Calif., March 10, 2011 ? Affymax, Inc. (Nasdaq: AFFY) today reported financial results for the year ended December 31, 2010. The net loss for the year ended December 31, 2010 was $14.1 million compared to a net loss of $76.5
March 10, 2011	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2011 AFFYMAX, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-33213 77-0579396 (Commission File Number) (
March 7, 2011	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 2, 2011 AFFYMAX, INC.
February 14, 2011	SC 13G/A	SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Affymax, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 00826A109 (CUSIP Number) December 31, 2010 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule
February 10, 2011	SC 13G/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 5)* AFFYMAX, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 00826A 10 9 (CUSIP Number) De UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 5)* AFFYMAX, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 00826A 10 9 (CUSIP Number) December 31, 2010 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedul
February 10, 2011	SC 13G/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G (Amendment No. 1) UNDER THE SECURITIES EXCHANGE ACT OF 19341 Affymax, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) (CU UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G (Amendment No.
February 9, 2011	SC 13G/A	UNITED STATES UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* AFFYMAX INC (Name of Issuer) COMMON STOCK (Title of Class of Securities) 00826A109 (CUSIP Number) DECEMBER 31, 2010 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is
February 4, 2011	EX-99.1	AFFYMAX ANNOUNCES APPOINTMENT OF HERB CROSS AS CHIEF FINANCIAL OFFICER Exhibit 99.1 Contacts: Sylvia Wheeler Executive Director, Corporate Communications Affymax, Inc. 650-812-8861 AFFYMAX ANNOUNCES APPOINTMENT OF HERB CROSS AS CHIEF FINANCIAL OFFICER PALO ALTO, Calif., February 4, 2011 — Affymax, Inc. (Nasdaq: AFFY) today announced that Herb Cross, the company’s vice president of finance and chief accounting officer, will become Affymax’s chief financial officer eff
February 4, 2011	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 31, 2011 AFFYMAX, INC. (Exa UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 31, 2011 AFFYMAX, INC.
January 25, 2011	SC 13D/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Affymax, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 00826A109 (CUSIP Number) Ivy Dodes Credit Suisse Eleven Madison Avenue, New York, NY 10010 (212) 325-2000 (Name, Address and Telephone Number of Pers
January 21, 2011	S-8	As filed with the Securities and Exchange Commission on January 21, 2011 As filed with the Securities and Exchange Commission on January 21, 2011 Registration No.
January 14, 2011	EX-99	EX-99 Exhibit 99.1 (1) Kathleen D. LaPorte ("LaPorte"), in her capacity as a member of the investment committees of DLJCC (as defined below) and of DLJLBO (as defined below), may be deemed to beneficially own the shares as to which this Form 4 relates. Ms. LaPorte disclaims beneficial ownership of such shares except to the extent of her pecuniary interest therein. Sprout Capital IX, L.P. ("Sprout IX"),
January 12, 2011	EX-99	EX-99 Exhibit 99.1 (1) Kathleen D. LaPorte ("LaPorte"), in her capacity as a member of the investment committees of DLJCC (as defined below) and of DLJLBO (as defined below), may be deemed to beneficially own the shares as to which this Form 4 relates. Ms. LaPorte disclaims beneficial ownership of such shares except to the extent of her pecuniary interest therein. Sprout Capital IX, L.P. ("Sprout IX"),
January 6, 2011	EX-99.1	AFFYMAX ANNOUNCES APPOINTMENT OF JOHN ORWIN AS CEO AND A MEMBER OF THE BOARD OF DIRECTORS Orwin to lead company into commercialization; Morris to consult through September 2011 Exhibit 99.1 Contacts: Sylvia Wheeler Vice President, Corporate Communications Affymax, Inc. 650-812-8861 AFFYMAX ANNOUNCES APPOINTMENT OF JOHN ORWIN AS CEO AND A MEMBER OF THE BOARD OF DIRECTORS Orwin to lead company into commercialization; Morris to consult through September 2011 PALO ALTO, Calif., January 6, 2011 — Affymax, Inc. (Nasdaq: AFFY) today announced that the company’s board of directo
January 6, 2011	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 5, 2011 AFFYMAX, INC. (Exac UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 5, 2011 AFFYMAX, INC.
November 29, 2010	8-K	Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 29, 2010 AFFYMAX, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-33213 77-0579396 (Commission File Number
November 29, 2010	EX-99.1	AFFYMAX AND TAKEDA CONFIRM U.S. REGISTRATION STRATEGY FOR INVESTIGATIONAL DRUG, HEMATIDE™/PEGINESATIDE, FOLLOWING MEETING WITH FDA - Companies Confirm Q2 2011 Timeline for NDA Submission — Exhibit 99.1 Corporate Contacts: Sylvia Wheeler Vice President, Corporate Communications Affymax, Inc. 650-812-8861 Toshiyuki Ikeuchi Corporate Communications Takeda Pharmaceutical Company Limited +1 81-3-3278-2037 Josephine Zammuto Corporate Communications Takeda Global Research & Development Center, Inc., U.S. 224-554-2795 AFFYMAX AND TAKEDA CONFIRM U.S. REGISTRATION STRATEGY FOR INVESTIGATIONAL
November 16, 2010	EX-99.1	AFFYMAX NAMES HERB CROSS AS CHIEF ACCOUNTING OFFICER AND VICE PRESIDENT OF FINANCE Exhibit 99.1 Contacts: Sylvia Wheeler Executive Director, Corporate Communications Affymax, Inc. 650-812-8861 AFFYMAX NAMES HERB CROSS AS CHIEF ACCOUNTING OFFICER AND VICE PRESIDENT OF FINANCE PALO ALTO, Calif., November 16, 2010 ? Affymax, Inc. (Nasdaq: AFFY) today announced that Herb Cross, a Certified Public Accountant and financial executive with more than sixteen years of experience, has join
November 16, 2010	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 15, 2010 AFFYMAX, INC.
November 5, 2010	EX-99.1	AFFYMAX? REPORTS THIRD QUARTER 2010 FINANCIAL RESULTS Exhibit 99.1 Corporate Contact: Sylvia Wheeler Vice President, Corporate Communications Affymax, Inc. 650-812-8861 AFFYMAX? REPORTS THIRD QUARTER 2010 FINANCIAL RESULTS PALO ALTO, Calif., November 5, 2010 ? Affymax, Inc. (Nasdaq: AFFY) today reported financial results for the third quarter ended September 30, 2010. The net loss for the third quarter of 2010 was $12.0 million compared to a net loss
November 5, 2010	EX-10.40	AMENDMENT TO EMPLOYMENT AGREEMENT EXHIBIT 10.40 AMENDMENT TO EMPLOYMENT AGREEMENT This AMENDMENT TO EMPLOYMENT AGREEMENT (?Amendment?) is entered into by and between ANNE-MARIE DULIEGE (?Executive?) and Affymax, Inc. (the ?Company?), effective as of September 23, 2010 (the ?Effective Date?). WHEREAS, the Company retains the services of Executive pursuant to that certain Employment Agreement dated December 17, 2008 (the ?Employment
November 5, 2010	EX-10.37	AMENDMENT TO EMPLOYMENT AGREEMENT EXHIBIT 10.37 AMENDMENT TO EMPLOYMENT AGREEMENT This AMENDMENT TO EMPLOYMENT AGREEMENT (?Amendment?) is entered into by and between ARLENE M. MORRIS (?Executive?) and Affymax, Inc. (the ?Company?), effective as of September 23, 2010 (the ?Effective Date?). WHEREAS, the Company retains the services of Executive pursuant to that certain Employment Agreement dated December 17, 2008 (the ?Employment A
November 5, 2010	EX-10.41	AMENDMENT TO EMPLOYMENT AGREEMENT EXHIBIT 10.41 AMENDMENT TO EMPLOYMENT AGREEMENT This AMENDMENT TO EMPLOYMENT AGREEMENT (“Amendment”) is entered into by and between ROBERT F. VENTEICHER (“Executive”) and Affymax, Inc. (the “Company”), effective as of September 23, 2010 (the “Effective Date”). WHEREAS, the Company retains the services of Executive pursuant to that certain Employment Agreement dated December 17, 2008 (the “Employme
November 5, 2010	EX-10.39	AMENDMENT TO EMPLOYMENT AGREEMENT EXHIBIT 10.39 AMENDMENT TO EMPLOYMENT AGREEMENT This AMENDMENT TO EMPLOYMENT AGREEMENT (“Amendment”) is entered into by and between PAUL B. CLEVELAND (“Executive”) and Affymax, Inc. (the “Company”), effective as of September 23, 2010 (the “Effective Date”). WHEREAS, the Company retains the services of Executive pursuant to that certain Employment Agreement dated December 17, 2008 (the “Employment
November 5, 2010	EX-10.38	AMENDMENT TO EMPLOYMENT AGREEMENT EXHIBIT 10.38 AMENDMENT TO EMPLOYMENT AGREEMENT This AMENDMENT TO EMPLOYMENT AGREEMENT (“Amendment”) is entered into by and between JOHN A. ORWIN (“Executive”) and Affymax, Inc. (the “Company”), effective as of September 23, 2010 (the “Effective Date”). WHEREAS, the Company retains the services of Executive pursuant to that certain Employment Agreement dated February 19, 2010 (the “Employment Agre
November 5, 2010	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 5, 2010 AFFYMAX, INC. (E UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 5, 2010 AFFYMAX, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-33213 77-0579396 (Commission File Number)
November 5, 2010	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2010 o TRANSITION REPORT PURSUANT Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2010 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-33213
October 18, 2010	424B5	999,061 Shares Affymax, Inc. Common Stock Table of Contents Filed Pursuant to Rule 424(b)(5) Registration Statement No. 333-149772 PROSPECTUS SUPPLEMENT To Prospectus dated September 25, 2009 999,061 Shares Affymax, Inc. Common Stock Pursuant to this prospectus supplement and the accompanying prospectus, we are offering 999,061 shares of our common stock to Azimuth Opportunity Ltd., or Azimuth, pursuant to a Common Stock Purchase Agreemen
October 18, 2010	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 15, 2010 AFFYMAX, INC.
October 6, 2010	EX-99.1	AFFYMAX® ANNOUNCES DECISION IN ARBITRATION AGAINST JNJ Exhibit 99.1 Corporate Contact: Sylvia Wheeler Vice President, Corporate Communications Affymax, Inc. 650-812-8861 AFFYMAX? ANNOUNCES DECISION IN ARBITRATION AGAINST JNJ PALO ALTO, Calif., October 6, 2010 ? Affymax, Inc. (Nasdaq: AFFY) today announced that it has received a decision from the arbitration panel reviewing its dispute against certain subsidiaries of Johnson and Johnson (JNJ). The pane
October 6, 2010	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 6, 2010 AFFYMAX, INC.
September 24, 2010	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 22, 2010 AFFYMAX, INC.
September 20, 2010	8-K	Financial Statements and Exhibits, Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 17, 2010 AFFYMAX, INC.
September 20, 2010	EX-10.36	AMENDMENT NO. 1 TO COMMON STOCK PURCHASE AGREEMENT Exhibit 10.36 AMENDMENT NO. 1 TO COMMON STOCK PURCHASE AGREEMENT This Amendment No. 1 (the “Amendment”) is entered into this 17th day of September 2010 (“Amendment Effective Date”) by and between Azimuth Opportunity Ltd., an international business company incorporated under the laws of the British Virgin Islands (the “Investor”), and Affymax, Inc., a corporation organized and existing under the la
September 15, 2010	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 13, 2010 AFFYMAX, INC.
August 19, 2010	SC 13D/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Affymax, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 00826A109 (CUSIP Number) Ivy Dodes Credit Suisse Eleven Madison Avenue, New York, NY 10010 (212) 325-2000 (Name, Address and Telephone Number of Pers
August 11, 2010	EX-99.1	(1) In accordance with Securities and Exchange Commission Release No. 34-39538 (January 12, 1998), this Form 4 is being filed by Credit Suisse AG (the ?Bank?), a Swiss bank, on behalf of its subsidiaries to the extent that they constitute the Investm Exhibit 99.1 (1) In accordance with Securities and Exchange Commission Release No. 34-39538 (January 12, 1998), this Form 4 is being filed by Credit Suisse AG (the ?Bank?), a Swiss bank, on behalf of its subsidiaries to the extent that they constitute the Investment Banking division (the ?Investment Banking division?), the Alternative Investments business (the ?AI Business?) within the Asset Manag
August 11, 2010	EX-99	EX-99 Exhibit 99.1 (1) Kathleen D. LaPorte ("LaPorte"), in her capacity as a member of the investment committees of DLJCC (as defined below) and of DLJLBO (as defined below), may be deemed to beneficially own the shares as to which this Form 4 relates. Ms. LaPorte disclaims beneficial ownership of such shares except to the extent of her pecuniary interest therein. Sprout Capital IX, L.P. ("Sprout IX"),
August 5, 2010	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2010 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-33213 AFFY
August 5, 2010	EX-99.1	AFFYMAX® REPORTS SECOND QUARTER 2010 FINANCIAL RESULTS EXHIBIT 99.1 Corporate Contact: Sylvia Wheeler Vice President, Corporate Communications Affymax, Inc. 650-812-8861 AFFYMAX® REPORTS SECOND QUARTER 2010 FINANCIAL RESULTS PALO ALTO, Calif., August 4, 2010 — Affymax, Inc. (Nasdaq: AFFY) today reported financial results for the second quarter ended June 30, 2010. Net income for the second quarter of 2010 was $17.3 million compared to a net loss of $2
August 5, 2010	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 4, 2010 AFFYMAX, INC. (Exa UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 4, 2010 AFFYMAX, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-33213 77-0579396 (Commission File Number) (
August 5, 2010	EX-10.35	FIFTH AMENDMENT Exhibit 10.35 FIFTH AMENDMENT THIS FIFTH AMENDMENT (this “Amendment”) is made and entered into as of May 20th, 2010, by and between CA-FOOTHILL RESEARCH CENTER LIMITED PARTNERSHIP, a Delaware limited partnership (“Landlord”), and AFFYMAX, INC., a Delaware corporation (“Tenant”). RECITALS A. Landlord (as successor in interest by conversion to EOP-Foothill Research Center, L.L.C., a Delaware limited
June 21, 2010	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 21, 2010 AFFYMAX, INC.
June 21, 2010	EX-99.1	AFFYMAX AND TAKEDA ANNOUNCE PHASE 3 TRIALS MEET PRIMARY ENDPOINTS FOR INVESTIGATIONAL DRUG, HEMATIDE™/PEGINESATIDE, TO TREAT ANEMIA IN CHRONIC RENAL FAILURE WITH SOME DIFFERENCES NOTED IN SECONDARY ANALYSES Exhibit 99.1 Corporate Contact: Sylvia Wheeler Vice President, Corporate Communications Affymax, Inc. 650-812-8861 Josephine Zammuto Corporate Communications Takeda Global Research & Development Center, Inc. 224-532-0716 Seizo Masuda Corporate Communications Takeda Pharmaceutical Company Limited +1 81-3-33278-2037 AFFYMAX AND TAKEDA ANNOUNCE PHASE 3 TRIALS MEET PRIMARY ENDPOINTS FOR INVESTIGATIONA
May 26, 2010	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 24, 2010 AFFYMAX, INC.
May 25, 2010	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 20, 2010 AFFYMAX, INC. (Exact n UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 20, 2010 AFFYMAX, INC.
May 10, 2010	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6, 2010 AFFYMAX, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-33213 77-0579396 (Commission File Number) (IRS
May 10, 2010	EX-99.1	AFFYMAX® REPORTS FIRST QUARTER 2010 FINANCIAL RESULTS Exhibit 99.1 Corporate Contact: Sylvia Wheeler Vice President, Corporate Communications Affymax, Inc. 650-812-8861 AFFYMAX® REPORTS FIRST QUARTER 2010 FINANCIAL RESULTS PALO ALTO, Calif., May 6, 2010 — Affymax, Inc. (Nasdaq: AFFY) today reported financial results for the first quarter ended March 31, 2010. The net loss for the first quarter of 2010 was $7.9 million compared to a net loss of $21.7
May 6, 2010	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2010 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-33213 AFF
May 6, 2010	EX-10.34	AFFYMAX INC. EXECUTIVE EMPLOYMENT AGREEMENT John A. Orwin EXHIBIT 10.34 AFFYMAX INC. EXECUTIVE EMPLOYMENT AGREEMENT for John A. Orwin This Employment Agreement (“Agreement”) is entered into by and between John A. Orwin (“Executive”) and Affymax Inc., (the “Company”), effective as of February 19, 2010 (the “Effective Date”). WHEREAS, the Company desires to employ Executive to provide personal services to the Company, and wishes to provide Executive with c
April 20, 2010	CORRESP	April 20, 2010 Affymax, Inc. 4001 Miranda Avenue Palo Alto, California 94304 650 812 8700 TELEPHONE 650 424 0832 FACSIMILE www.affymax.com WEB April 20, 2010 United States Securities and Exchange Commission Mail Stop 4720 100 F Street N.E. Washington, D.C. 20549 Attn: John L. Krug RE: Affymax, Inc. (the ?Company?) Registration Statement on Form S-3 (File No. 333-165220) (the ?Registration Statement?) Ladies and
April 15, 2010	CORRESP	Lena R. Haslund VIA EDGAR (650) 843-5802 [email protected] Lena R. Haslund VIA EDGAR (650) 843-5802 [email protected] April 15, 2010 United States Securities and Exchange Commission Mail Stop 4720 100 F Street N.E. Washington, D.C. 20549 Attn: John L. Krug RE: Affymax, Inc. (the “Company”) Registration Statement on Form S-3 (File No. 333-165220) (the “Registration Statement”) Ladies and Gentlemen: The undersigned, as counsel for the registrant, hereby r
April 13, 2010	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 12, 2010 AFFYMAX, INC.
April 13, 2010	EX-99.1	AFFYMAX NAMES JOHN A. ORWIN PRESIDENT AND CHIEF OPERATING OFFICER Exhibit 99.1 Contacts: Sylvia Wheeler Vice President, Corporate Communications Affymax, Inc. 650-812-8861 AFFYMAX NAMES JOHN A. ORWIN PRESIDENT AND CHIEF OPERATING OFFICER PALO ALTO, Calif., April 12, 2010 — Affymax, Inc. (Nasdaq: AFFY) today announced that John A. Orwin, an executive with over 20 years of experience in the biotechnology and pharmaceutical industries, has joined the company as pre
April 8, 2010	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) QuickLinks - Click here to rapidly navigate through this document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
March 4, 2010	S-8	As filed with the Securities and Exchange Commission on March 4, 2010 As filed with the Securities and Exchange Commission on March 4, 2010 Registration No.
March 4, 2010	EX-99.1	AFFYMAX® REPORTS YEAR END 2009 FINANCIAL RESULTS Exhibit 99.1 Corporate Contact: Sylvia Wheeler Executive Director, Corporate Communications Affymax, Inc. 650-812-8861 AFFYMAX® REPORTS YEAR END 2009 FINANCIAL RESULTS PALO ALTO, Calif., March 4, 2010 — Affymax, Inc. (Nasdaq: AFFY) today reported financial results for the year ended December 31, 2009. The net loss for the year 2009 was $76.5 million compared to a net loss of $86.5 million for the
March 4, 2010	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 4, 2010 AFFYMAX, INC. (Exac UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 4, 2010 AFFYMAX, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-33213 77-0579396 (Commission File Number) (I
March 4, 2010	EX-10.5	AFFYMAX, INC. AMENDED AND RESTATED 2006 EQUITY INCENTIVE PLAN APPROVED BY THE BOARD: JULY 7, 2006 APPROVED BY THE STOCKHOLDERS: NOVEMBER 22, 2006 AS AMENDED BY THE BOARD ON OCTOBER 29, 2009 TERMINATION DATE: JULY 6, 2016 EXHIBIT 10.5 AFFYMAX, INC. AMENDED AND RESTATED 2006 EQUITY INCENTIVE PLAN APPROVED BY THE BOARD: JULY 7, 2006 APPROVED BY THE STOCKHOLDERS: NOVEMBER 22, 2006 AS AMENDED BY THE BOARD ON OCTOBER 29, 2009 TERMINATION DATE: JULY 6, 2016 1. GENERAL. (a) Successor and Continuation of Prior Plan. The Plan is intended as the successor to and continuation of the Affymax, Inc. 2001 Stock Option/Stock Issua
March 4, 2010	EX-4.16	AFFYMAX, INC. , AS WARRANT AGENT FORM OF COMMON STOCK WARRANT AGREEMENT DATED AS OF Exhibit 4.16 AFFYMAX, INC. and , AS WARRANT AGENT FORM OF COMMON STOCK WARRANT AGREEMENT DATED AS OF AFFYMAX, INC. FORM OF COMMON STOCK WARRANT AGREEMENT COMMON STOCK WARRANT AGREEMENT (this ?Agreement?), dated as of between Affymax, Inc. , a Delaware corporation (the ?Company?) and , a [corporation] [national banking association] organized and existing under the laws of and having a corporate tru
March 4, 2010	EX-10.33	Account Number EXHIBIT 10.33 UBS Bank USA Variable Credit Line Account Number: (if applicable) Fixed Credit Line Account Number: (if applicable) Credit Line Account Application and Agreement for Organizations and Businesses HB SS# / TIN Internal Use Only For Internal Use Only Variable Credit Line Account at UBS Bank USA Fixed Credit Line Account at UBS Bank USA Collateral Account(s) at UBS Financial Services Inc
March 4, 2010	EX-4.12	AFFYMAX, INC., Dated as of [?], 200 Senior Debt Securities Exhibit 4.12 AFFYMAX, INC., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [?], 200 Senior Debt Securities TABLE OF CONTENTS PAGE ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 5 Section 2.01 Designation and Terms of Securities 5 Section 2.02 Form of Securities and Trustee?s Certificate 8 Sect
March 4, 2010	S-3	As filed with the Securities and Exchange Commission on March 4, 2010 Table of Contents As filed with the Securities and Exchange Commission on March 4, 2010 Registration No.
March 4, 2010	EX-4.17	AFFYMAX, INC. , AS WARRANT AGENT FORM OF PREFERRED STOCK WARRANT AGREEMENT DATED AS OF Exhibit 4.17 AFFYMAX, INC. and , AS WARRANT AGENT FORM OF PREFERRED STOCK WARRANT AGREEMENT DATED AS OF AFFYMAX, INC. FORM OF PREFERRED STOCK WARRANT AGREEMENT PREFERRED STOCK WARRANT AGREEMENT (this ?Agreement?), dated as of between Affymax, Inc. , a Delaware corporation (the ?Company?) and , a [corporation] [national banking association] organized and existing under the laws of and having a corp
March 4, 2010	EX-4.18	AFFYMAX, INC. , AS WARRANT AGENT FORM OF DEBT SECURITIES WARRANT AGREEMENT DATED AS OF Exhibit 4.18 AFFYMAX, INC. and , AS WARRANT AGENT FORM OF DEBT SECURITIES WARRANT AGREEMENT DATED AS OF AFFYMAX, INC. FORM OF DEBT SECURITIES WARRANT AGREEMENT DEBT SECURITIES WARRANT AGREEMENT (this “Agreement”), dated as of between AFFYMAX, INC., a Delaware corporation (the “Company”) and , a [corporation] [national banking association] organized and existing under the laws of and having a corpo
March 4, 2010	EX-12.1	Statement of Computation of Ratio of Earnings to Fixed Charges (in thousands) Exhibit 12.1 Statement of Computation of Ratio of Earnings to Fixed Charges (in thousands) Year Ended December 31, 2009 2008 2007 2006 2005 Earnings: Net loss before income taxes $ (77,942 ) $ (86,228 ) $ (37,712 ) $ (48,288 ) $ (32,576 ) Plus: Fixed charges 715 879 812 1,051 1,036 Earnings, as defined $ (77,227 ) $ (86,349 ) $ (36,900 ) $ (47,237 ) $ (31,540 ) Fixed Charges: Interest expense on i
March 4, 2010	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Use these links to rapidly review the document TABLE OF CONTENTS Item 8. Financial Statements and Supplementary Data. Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ý ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2009 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15
March 4, 2010	EX-4.13	AFFYMAX, INC., Dated as of [?], 200 Subordinated Debt Securities Exhibit 4.13 AFFYMAX, INC., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [?], 200 Subordinated Debt Securities TABLE OF CONTENTS PAGE ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 5 Section 2.01 Designation and Terms of Securities 5 Section 2.02 Form of Securities and Trustee?s Certificate
March 3, 2010	SC 13G/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4)* AFFYMAX, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 00826A 10 9 (CUSIP Number) De UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4)* AFFYMAX, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 00826A 10 9 (CUSIP Number) December 31, 2009 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule pursuant to which this Schedul
February 16, 2010	SC 13G/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b) (c) and (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2(b) (Amendment No. SC 13G/A 1 b79536bsc13gza.htm AFFYMAX, INC. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b) (c) and (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2(b) (Amendment No. 2)* Affymax, Inc. (Name of Issuer) Common Stock, Par Value $0.001 Per Share (Title of Class of Securities

AFFY / Affymax, Inc. - SEC-arkiveringar, Årsredovisning, Fullmaktsutlåtande

Grundläggande statistik

SEC Filings

SEC Filings (Chronological Order)